IFLYTEK(SZ:002230) Zhong Guo Ji Jin Bao·2025-06-25 16:16Core Viewpoint - The company is entering the international market with its medical AI model, aiming for profitability within 1-2 years despite current losses [4][6]. Group 1: Global Expansion of Medical AI - On June 24, the company launched the international version of its medical AI model, Spark Medical Model V2.5, and the Hong Kong version of the iFlytek Xiaoyi App [3]. - Hong Kong is viewed as a strategic base for the company's internationalization efforts, facilitating the training of data for global products [3]. - The upgraded model supports local language scenarios and aims to collaborate with Western medical professionals in Hong Kong to develop products for global markets [3]. Group 2: Financial Performance and Commercialization - The company reported a revenue of 734 million yuan for 2024, a 32% increase year-on-year, but also a net loss of 133 million yuan, which is an 8.5% reduction compared to 2023 [5]. - The company has seen significant growth in both B-end and C-end business revenues, with C-end patient services generating 211 million yuan (up 56.6%) and B-end hospital services reaching 132 million yuan (up 103.4%) [5]. - The company’s AI assistant has been deployed in 69,200 grassroots medical institutions, providing over 1 billion AI-assisted diagnoses and correcting 1.75 million diagnoses [5].